PL2595484T3 - Zastosowanie cyklicznych pochodnych amidowych do leczenia zaburzeń snu - Google Patents

Zastosowanie cyklicznych pochodnych amidowych do leczenia zaburzeń snu

Info

Publication number
PL2595484T3
PL2595484T3 PL11810349T PL11810349T PL2595484T3 PL 2595484 T3 PL2595484 T3 PL 2595484T3 PL 11810349 T PL11810349 T PL 11810349T PL 11810349 T PL11810349 T PL 11810349T PL 2595484 T3 PL2595484 T3 PL 2595484T3
Authority
PL
Poland
Prior art keywords
treatment
sleep disorders
amide derivatives
cyclic amide
cyclic
Prior art date
Application number
PL11810349T
Other languages
English (en)
Inventor
Remy Henri Luthringer
Lorenzo Pellegrini
Argeris N. Karabelas
Original Assignee
Minerva Neurosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minerva Neurosciences, Inc. filed Critical Minerva Neurosciences, Inc.
Publication of PL2595484T3 publication Critical patent/PL2595484T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • HELECTRICITY
    • H04ELECTRIC COMMUNICATION TECHNIQUE
    • H04LTRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00Arrangements affording multiple use of the transmission path
    • H04L5/0001Arrangements for dividing the transmission path
    • H04L5/0003Two-dimensional division
    • H04L5/0005Time-frequency
    • H04L5/0007Time-frequency the frequencies being orthogonal, e.g. OFDM(A) or DMT
    • H04L5/001Time-frequency the frequencies being orthogonal, e.g. OFDM(A) or DMT the frequencies being arranged in component carriers
    • HELECTRICITY
    • H04ELECTRIC COMMUNICATION TECHNIQUE
    • H04LTRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00Arrangements affording multiple use of the transmission path
    • H04L5/0001Arrangements for dividing the transmission path
    • H04L5/0014Three-dimensional division
    • H04L5/0016Time-frequency-code
    • HELECTRICITY
    • H04ELECTRIC COMMUNICATION TECHNIQUE
    • H04LTRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00Arrangements affording multiple use of the transmission path
    • H04L5/0001Arrangements for dividing the transmission path
    • H04L5/0014Three-dimensional division
    • H04L5/0016Time-frequency-code
    • H04L5/0019Time-frequency-code in which one code is applied, as a temporal sequence, to all frequencies
    • HELECTRICITY
    • H04ELECTRIC COMMUNICATION TECHNIQUE
    • H04LTRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00Arrangements affording multiple use of the transmission path
    • H04L5/003Arrangements for allocating sub-channels of the transmission path
    • H04L5/0048Allocation of pilot signals, i.e. of signals known to the receiver
    • HELECTRICITY
    • H04ELECTRIC COMMUNICATION TECHNIQUE
    • H04LTRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00Arrangements affording multiple use of the transmission path
    • H04L5/003Arrangements for allocating sub-channels of the transmission path
    • H04L5/0048Allocation of pilot signals, i.e. of signals known to the receiver
    • H04L5/005Allocation of pilot signals, i.e. of signals known to the receiver of common pilots, i.e. pilots destined for multiple users or terminals
    • HELECTRICITY
    • H04ELECTRIC COMMUNICATION TECHNIQUE
    • H04LTRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00Arrangements affording multiple use of the transmission path
    • H04L5/003Arrangements for allocating sub-channels of the transmission path
    • H04L5/0053Allocation of signalling, i.e. of overhead other than pilot signals
    • HELECTRICITY
    • H04ELECTRIC COMMUNICATION TECHNIQUE
    • H04WWIRELESS COMMUNICATION NETWORKS
    • H04W4/00Services specially adapted for wireless communication networks; Facilities therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Signal Processing (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Dentistry (AREA)
  • Agronomy & Crop Science (AREA)
  • Anesthesiology (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL11810349T 2010-07-20 2011-07-20 Zastosowanie cyklicznych pochodnych amidowych do leczenia zaburzeń snu PL2595484T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36607510P 2010-07-20 2010-07-20
PCT/US2011/044697 WO2012012542A1 (en) 2010-07-20 2011-07-20 Methods of use of cyclic amide derivatives to treat schizophrenia
EP11810349.8A EP2595484B1 (en) 2010-07-20 2011-07-20 Use of cyclic amide derivatives to treat sleep disorders

Publications (1)

Publication Number Publication Date
PL2595484T3 true PL2595484T3 (pl) 2018-03-30

Family

ID=45497166

Family Applications (2)

Application Number Title Priority Date Filing Date
PL16181339.9T PL3135286T3 (pl) 2010-07-20 2011-07-20 Sposoby zastosowania pochodnych amidów cyklicznych do leczenia schizofrenii i jej objawów
PL11810349T PL2595484T3 (pl) 2010-07-20 2011-07-20 Zastosowanie cyklicznych pochodnych amidowych do leczenia zaburzeń snu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL16181339.9T PL3135286T3 (pl) 2010-07-20 2011-07-20 Sposoby zastosowania pochodnych amidów cyklicznych do leczenia schizofrenii i jej objawów

Country Status (22)

Country Link
US (3) US20180155318A1 (pl)
EP (4) EP4494704A3 (pl)
JP (2) JP6053678B2 (pl)
KR (1) KR101867633B1 (pl)
CN (1) CN103220910B (pl)
BR (1) BR112013001303A2 (pl)
CA (2) CA2806017C (pl)
DK (2) DK2595484T3 (pl)
ES (2) ES2963362T3 (pl)
FI (1) FI3135286T3 (pl)
HR (1) HRP20231446T1 (pl)
HU (1) HUE064157T2 (pl)
LT (1) LT3135286T (pl)
NO (1) NO2595484T3 (pl)
PL (2) PL3135286T3 (pl)
PT (2) PT2595484T (pl)
RS (1) RS64819B1 (pl)
RU (1) RU2576611C2 (pl)
SI (1) SI3135286T1 (pl)
SM (1) SMT202300413T1 (pl)
TW (1) TWI583679B (pl)
WO (1) WO2012012542A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3227273B1 (en) 2014-12-02 2022-02-09 Minerva Neurosciences, Inc. Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
CN113694065A (zh) * 2016-05-25 2021-11-26 田边三菱制药株式会社 用于治疗非精神分裂症患者中的阴性症状的组合物和方法
WO2018237207A1 (en) 2017-06-21 2018-12-27 Minerva Neurosciences, Inc. Gastro-resistant controlled release oral dosage forms
US20200230127A1 (en) 2017-10-10 2020-07-23 Neurocrine Biosciences, Inc. Methods for the Administration of Certain VMAT2 Inhibitors
WO2020041504A1 (en) * 2018-08-21 2020-02-27 Minerva Neurosciences, Inc. Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3888340T2 (de) * 1988-01-21 1994-06-30 Merrell Dow Pharma Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit.
KR927002347A (ko) * 1989-10-27 1992-09-03 레이몬드 지. 아너 (n-프탈이미도알킬) 피페리딘
IE903857A1 (en) * 1989-10-27 1991-05-08 Du Pont Merck Pharma (N-Phthalimidoalkyl)Piperidines
AU2001234175B2 (en) * 2000-02-29 2004-10-07 Mitsubishi Pharma Corporation Novel cyclic amide derivatives
US6335371B1 (en) * 2000-11-28 2002-01-01 Orion Corporation Method for inducing cognition enhancement
PE20061490A1 (es) * 2005-06-06 2007-02-09 Merck Sharp & Dohme Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1
TW200817400A (en) * 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them

Also Published As

Publication number Publication date
LT3135286T (lt) 2023-11-10
JP2013531072A (ja) 2013-08-01
SMT202300413T1 (it) 2024-01-10
ES2656313T3 (es) 2018-02-26
EP3335731A1 (en) 2018-06-20
PT2595484T (pt) 2018-01-22
SI3135286T1 (sl) 2024-02-29
RU2013107382A (ru) 2014-08-27
EP2595484A4 (en) 2014-04-23
FI3135286T3 (fi) 2023-11-15
WO2012012542A1 (en) 2012-01-26
KR20130129905A (ko) 2013-11-29
DK2595484T3 (en) 2018-01-22
DK3135286T3 (da) 2023-11-27
EP4494704A3 (en) 2025-04-23
JP6200561B2 (ja) 2017-09-20
CN103220910A (zh) 2013-07-24
EP4494704A2 (en) 2025-01-22
BR112013001303A2 (pt) 2016-05-17
EP2595484A1 (en) 2013-05-29
ES2963362T3 (es) 2024-03-26
HRP20231446T1 (hr) 2024-03-01
CA3117855A1 (en) 2012-01-26
KR101867633B1 (ko) 2018-06-15
TW201211021A (en) 2012-03-16
US20220274951A1 (en) 2022-09-01
EP2595484B1 (en) 2017-10-18
EP3135286B1 (en) 2023-09-06
US20250179044A1 (en) 2025-06-05
RU2576611C2 (ru) 2016-03-10
HUE064157T2 (hu) 2024-02-28
NO2595484T3 (pl) 2018-03-17
US20180155318A1 (en) 2018-06-07
CA3117855C (en) 2023-01-10
TWI583679B (zh) 2017-05-21
CN103220910B (zh) 2016-05-11
EP3335731B1 (en) 2024-09-04
CA2806017A1 (en) 2012-01-26
PL3135286T3 (pl) 2024-04-22
RS64819B1 (sr) 2023-12-29
JP2017031159A (ja) 2017-02-09
PT3135286T (pt) 2023-11-28
CA2806017C (en) 2021-06-29
EP3135286A1 (en) 2017-03-01
JP6053678B2 (ja) 2016-12-27

Similar Documents

Publication Publication Date Title
LTC2435025I2 (lt) Veikliosios medžiagos tiekimas per kvėpavimo takus
AU339607S (en) Medical device for treatment of sleep disorders
DK2685887T3 (da) Personlig eeg-overvågningsindretning med elektrodevalidering
HRP20181378T1 (hr) Postupci liječenja pedijatrijskih pacijenata deksmedetomidinom
PT2919796T (pt) Utilização de akkermansia para o tratamento de distúrbios metabólicos
PL2544744T3 (pl) Element inhalatora
EP2593001C0 (en) NON-INVASIVE MONITORING OF PHYSIOLOGICAL CONDITIONS
IL228030B (en) Compounds for treating hyperuricemia and metabolic disorders associated with hyperuricemia
DE112013002528A5 (de) Kopfhalterung zur Fixierung des Kopfes von Patienten
PL2582366T3 (pl) Kombinacja farmaceutyczna do leczenia bólu
IL223286A0 (en) Piperidine derivatives and their use for the treatment of metabolic disorders
IL225668A (en) Formulations for the treatment of disorders of the upper respiratory tract
PL3133396T3 (pl) Sposób leczenia z zastosowaniem leków wychwytujących amoniak
DK2838539T3 (da) Østrogenderivater til anvendelse i behandlingen af neurologiske forstyrrelser
IL231092A0 (en) Treatment of rhinitis
HUE040085T2 (hu) PDE7 inhibitorok alkalmazása mozgási rendellenességek kezelésére
PL2718434T3 (pl) Kompozycje i sposoby leczenia choroby trzewnej
PL2900230T3 (pl) Związki do leczenia otyłości i sposoby ich zastosowania
IL225896A0 (en) Treatment of mecp-2 related disorders
IL234606B (en) Novel methods and composition for treatment of disease
EP2861244A4 (en) TREATMENT OF SLEEP APNEA
BR112012023392A2 (pt) dispositivo relacionado com apneia do sono
IL227747A0 (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
HUE058736T2 (hu) Gyûrûs amidszármazékok alkalmazási módszerei szigma receptor közvetített rendellenességek kezelésére
HRP20160918T1 (hr) Postupak pripreme 6-klor-2,3,4,9-tetrahidro-1h-karbazol-1-karboksamida i njegovih prekursora